Use of NK-1 receptor antagonist serlopitant in pruritus

A method of administering a therapeutically effective amount of 3-[(3aR,4R,5S,7aS)-5-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-4-(4-fluorophenyl)-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl]cyclopent-2-en-1-one (serlopitant) or a pharmaceutically acceptable salt, solvate or polymorph thereof and a corticosteroid to a patient with a viral infection in need of treatment;

• wherein serlopitant is administered one, two, three or more times per day, orally, by injection or infusion and the corticosteroid is administered one, two, three or more times per day, intranasally, pulmonarily, by injection or infusion;
• wherein at least one loading dose of serlopitant is administered, and at least one therapeutically effective maintenance dose of serlopitant is subsequently administered, wherein the at least one loading dose is five times, four times, three times or two times larger than the at least one therapeutically effective maintenance dose or the at least one loading dose is 0.75 mg, 3 mg, or 15 mg, and the at least one therapeutically effective maintenance dose is 0.25 mg, 1 mg, or 5 mg;
• wherein about 0.1 mg to about 30 mg, or from about 1 mg to about 7.5 mg of serlopitant is administered daily;
• and
• wherein the corticosteroid is administered concurrently with or sequentially (before or after) administration of serlopitant.